ALCAM and neoplasm: For example, immunoliposomes coupled with anti-ALCAM single-chain antibody fragments (scFv) have been used to deliver anti-tumor agents to prostate cancer cells [220], opening avenues for the future design of functionalized nanotherapeutics targeting EndoA-mediated endocytic axes.